Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose escalation
Compose a Response to This Article
Other responses
No responses have been published for this article.
